Molecular imaging is one of the biggest hopes in cancer research because it is able to reveal pathological processes on the cellular level long before the first symptoms are apparent. Cancer cells can be identified very early, and can thus be prevented from developing into life-threatening tumours. Five well-known German pharmaceutical and medical device companies have now joined forces and are combining their know-how in the bid to turn molecular imaging methods into reality as soon as possible. Tuttlingen-based KARL STORZ GmbH is a partner in the project.
Further information:KARL STORZ GmbH & Co. KGDr. Martin LeonhardMittelstraße 878532 TuttlingenTel.: +49 (0)7461 708 - 702Fax: +49 (0)7461 708 - 75 702E-mail: M.Leonhard@karlstorz.de